Paclitaxel Articles
Novagali's oral paclitaxel enters Ph I
6 June 2005
Boston's Liberte: good 30-day safety data
6 June 2005
NICE: S-P
30 May 2005
Bayer/Onyx initiate PH III sorafenib trial
23 May 2005
Abraxane Ph II trial finishes recruitment
16 May 2005
Marshall Edwards drug effective in cancer
16 May 2005
Angiotech/Cook to start global trial for Zilver
16 May 2005
B-MS 1st-qtr 2005 income down 36%
9 May 2005
ARIAD kicks off Ph Ib trial of cancer drug
9 May 2005
Tapestry sees preclinical promise in taxane candidate
28 April 2005
FDA clears Antisoma's Ph II cancer trial
25 April 2005
France's Diatos opens subsidiary in USA
18 April 2005
APP reports start of Ph II trial of Abraxane/Herceptin
18 April 2005
Japan stock market week to April 4
11 April 2005
Targretin: endpoints missed in NSCLC trials
4 April 2005
Xyotax enters Phase III ovarian cancer trial
28 March 2005
J&J's Cypher stent not superior to BS' Taxus
14 March 2005
Scotland OKs Femara, rejects other drugs
14 March 2005
Strong results for APP's Abraxane
7 March 2005
Patient enrollment completed in ATLAS study for Taxus Liberte
28 February 2005
American PP announces Abraxane launch date
7 February 2005
FDA orphan status for Sonus' TOCOSOL
31 January 2005
EPO maintains Angiotech's paclitaxel-eluting stent patent
31 January 2005
Angiotech markets Taxus Liberte stent
24 January 2005
Abraxane cleared for breast cancer by FDA
17 January 2005
Diatos and MacroMed sign OncoGel deal
10 January 2005
Terumo initiates Nobori clinical study
10 January 2005
Gemzar combination with Taxol OKed in UK
13 December 2004
Guilford Pharma in $6M patent deal with Angiotech
27 September 2004
NeoPharm regains oncology products
27 September 2004
Integrated BioPharm to buy Hauser CRO
26 July 2004
Angiotech expects $3-$5M loss from stent recall
26 July 2004
Additional European patent on paciltaxel for Xechem
26 July 2004
Angiotech's stents recalled
12 July 2004
Mylan settles paclitaxel litigation
12 July 2004
Angiotech issues guidance for 2004-6
5 July 2004
Angiotech enrolls in pivotal vascular wrap study
5 July 2004
New use in EU for Roche's Herceptin
28 June 2004
Encouraging data for Bayer's BAY 43-9006 in melanoma
14 June 2004
FDA OKs Lilly's Gemzar for additional use
24 May 2004
B-MS reports 1st-qtr earnings jump 22%
3 May 2004
Kosan gets NCI grant to develop discodermolide analogue
12 April 2004
Abraxane filed for US approval
15 March 2004
FDA approval for Taxus Express stent
15 March 2004
IVAX enters European distributin deal with Mayne
1 March 2004
20% pharma sales rise boosts B-MS profits
9 February 2004
IVAX on track for new use of Paxene
2 February 2004
US state AG sues for Rx "overcharging"
2 February 2004
Cell Therapeutics and Novuspharma complete merger
5 January 2004
Sonus' Tocosol Paclitaxel fast-tracked
10 November 2003
New data for Taxotere in the MBC setting
6 October 2003
Profits down at Integrated Biopharma
6 October 2003
Bristol-Myers Squibb warned by FDA over Pravachol ads
18 August 2003
New findings for Antisoma's DMXAA
21 July 2003
Sonus sees small decline in 2nd-qtr loss
21 July 2003
Lilly's Gemzar cleared for breast cancer
30 June 2003
Profits down 11% at B-MS in first quarter
5 May 2003
NaPro to sell worldwide paclitaxel business
14 April 2003
Angiotech's psoriasis drug promising in Ph I
31 March 2003
Boston Sci's Taxus gains expedited FDA review
24 March 2003
Isis/Lilly's Affinitak disappoints in Ph III
24 March 2003
B-MS settles US FTC/states
17 March 2003
B-MS settles US FTC/states
17 March 2003
Boston Sci rolls out its Taxus coated stent
24 February 2003
IVAX's earnings fall on lost paclitaxel sales
24 February 2003
Sonus reports higher losses
10 February 2003
Angiotech completes acquisition of Cohesion Tech
10 February 2003
Boston Sci gets Euro OK for paclitaxel stent
27 January 2003
UK NICE revises advice on B-MS
27 January 2003
Angiotech plans stock split
27 January 2003
Bioxel enters R&D collaboration
20 January 2003
Angiotech says paclitaxel wrap effective
20 January 2003
Update - B-MS ready to settle generics- blocking charges
13 January 2003
Enzon pulls plug on PEG-paclitaxel
13 January 2003
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
